Speaker(s): 

Sydney Dyekhuizen PharmD, PGY1 resident, Geisinger - has nothing to disclose.

Tiffany Tang  PharmD, PGY1 resident, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher J DeFrancesco PharmD, Geisinger - has nothing to disclose.

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Identify innovative pharmacologic alternatives to statin therapy for reducing cardiovascular risk
2. Explore buprenorphine's indications for use in acute, ambulatory, and perioperative settings.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH, Anil Singh MD, Roop Parlapalli, MD, FHM, FACP, Mary Ellen Berry PA-C, and Carlena Miller CRNP have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None